Talphera Cuts Expenses 14 Percent
Talphera (NASDAQ:TLPH), a specialty pharmaceutical company developing therapies for medically supervised hospital settings, reported its second quarter 2025 results on August 14, 2025. The company posted an EPS loss of $0.10 (GAAP), which was better than the analyst consensus estimate of a $0.13 loss (GAAP). No revenue was recorded for the period, in line with expectations and the company’s pre-commercial stage. Overall, the quarter showed progress in cost controls and clinical pipeline advancement, but highlighted continuing capital constraints and the company’s dependence on successful trial enrollment and financing milestones.
Source: Analyst estimates for the quarter provided by FactSet.
Talphera develops hospital-focused therapies, specializing in treatments for acute and critical care settings. Its main asset, Niyad (nafamostat), is under late-stage clinical study as an anticoagulant for patients undergoing continuous renal replacement therapy (CRRT) in intensive care units.
Source Fool.com
